PT-141 (Bremelanotide) Mechanism of Action — Central Melanocortin Pathway

*Pharmacology of the cyclic heptapeptide PT-141 (bremelanotide): MC4R / MC3R agonism, central sexual response circuits, and distinction from PDE5-inhibitor mechanisms.*

Research Use Only. All material on this page is provided strictly for in vitro and in vivo laboratory research purposes. It is not medical advice and is not intended for human or veterinary therapeutic use.

Overview

PT-141 (bremelanotide) is a cyclic 7-amino-acid α-MSH analogue developed from melanotan-II. Unlike MT-2, PT-141 has minimal MC1R activity and acts primarily on the central melanocortin pathway.

Receptor Profile

• MC4R: primary high-affinity target — central sexual response
• MC3R: secondary activity — energy homeostasis, central appetite regulation
• MC1R: minimal activity — limited pigmentation effect vs MT-2
• MC5R: weak activity

Central Sexual Response Pathway

MC4R agonism in the medial preoptic area and paraventricular nucleus of the hypothalamus activates dopaminergic projections to the nucleus accumbens — a circuit distinct from vasodilation-driven mechanisms targeted by PDE5 inhibitors. This is the basis for PT-141's FDA approval (Vyleesi) for hypoactive sexual desire disorder in pre-menopausal women.

Pharmacokinetics

• Route: subcutaneous injection (autoinjector form approved)
• Tmax: ~1 h
• t½: ~2.7 h
• Distribution: modest plasma protein binding
• Excretion: ~64.8% in urine, ~22.8% in feces over 168 h

Distinction From PDE5 Inhibitors

• PT-141: central CNS mechanism, works on desire/arousal pathway
• Sildenafil/tadalafil: peripheral cGMP/NO mechanism, works on vasodilation
• The two mechanisms are pharmacologically complementary; the published RECONNECT trials evaluated PT-141 specifically for HSDD, not erectile vasodilation

Other Documented Effects

• Transient BP increase (~6 mmHg systolic); rare cases of more pronounced hypertension
• Nausea — most common adverse event, central MC-mediated
• Flushing
• Headache

Frequently Asked Research Questions

How is PT-141 different from sildenafil?

PT-141 acts centrally via MC4R agonism in hypothalamic sexual-response circuits, while PDE5 inhibitors act peripherally on cGMP-mediated vascular smooth-muscle relaxation. The mechanisms are pharmacologically complementary, not interchangeable.

Why does PT-141 not cause pigmentation like MT-2?

PT-141 has minimal MC1R activity. MT-2 is non-selective across MC1R/MC3R/MC4R/MC5R; PT-141 was engineered to favour MC4R/MC3R and consequently produces little pigmentation.

What is the FDA-approved indication?

Bremelanotide (Vyleesi, the PT-141 INN brand) was FDA-approved in 2019 for hypoactive sexual desire disorder in pre-menopausal women, on the basis of the RECONNECT trial program.

References

1. Drucker DJ. *Mechanisms of action and therapeutic application of GLP-1.* Cell Metab. 2018.

1. Coskun T, et al. *LY3298176 (tirzepatide) — discovery of a dual GIP/GLP-1 agonist.* Mol Metab. 2018.

1. Sikiric P, et al. *Stable gastric pentadecapeptide BPC-157.* Curr Pharm Des. 2018.

1. Goldstein AL, Hannappel E. *Thymosin β4 — actin sequestering and tissue repair.* Ann N Y Acad Sci. 2007.

1. Falutz J, et al. *Tesamorelin in HIV-associated lipodystrophy.* N Engl J Med. 2007.

1. Pfaus JG, et al. *Bremelanotide — central melanocortin agonism.* Curr Sex Health Rep. 2007.

1. Khavinson VK, et al. *Epitalon — pineal-tetrapeptide telomerase activation.* Bull Exp Biol Med. 2003.

1. Imai S, Guarente L. *NAD+ and sirtuins in aging and disease.* Trends Cell Biol. 2014.